HANSOH PHARMA buys 370,000 shares for RSU scheme at HK$39.11 each, spending HK$14.47 million

Bulletin Express04-30 18:45

Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) disclosed that the trustee of its Post-IPO Restricted Share Unit Scheme acquired 370,000 shares on the open market between 14 and 22 April 2026. The purchases, settled from 16 to 24 April, were executed at an average price of HK$39.1069 per share, bringing the cash outlay to approximately HK$14.47 million.

The newly acquired shares represent about 0.006% of Hansoh’s total issued share capital. Prior to the transaction, the RSU trustee held 1.19 million shares. Factoring in the April 17 issuance of 9.00 million new shares to the trustee under the scheme, the post-purchase holding rose to 10.56 million shares.

The board stated it will continue to monitor the scheme and may authorise further market purchases or RSU grants at its discretion, subject to Hong Kong Listing Rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145678598?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145678598","market":"us","top_or_hot":-1,"title":"HANSOH PHARMA buys 370,000 shares for RSU scheme at HK$39.11 each, spending HK$14.47 million","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) disclosed that the trustee of its Post-IPO Restricted Share Unit Scheme acquired 370,000 shares on the open market between 14 and 22 April 2026. The purchases, settled from 16 to 24 April, were executed at an average price of HK$39.1069 per share, bringing the cash outlay to approximately HK$14.47 million.</p>\n<p>The newly acquired shares represent about 0.006% of Hansoh’s total issued share capital. Prior to the transaction, the RSU trustee held 1.19 million shares. Factoring in the April 17 issuance of 9.00 million new shares to the trustee under the scheme, the post-purchase holding rose to 10.56 million shares.</p>\n<p>The board stated it will continue to monitor the scheme and may authorise further market purchases or RSU grants at its discretion, subject to Hong Kong Listing Rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA buys 370,000 shares for RSU scheme at HK$39.11 each, spending HK$14.47 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA buys 370,000 shares for RSU scheme at HK$39.11 each, spending HK$14.47 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-30 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) disclosed that the trustee of its Post-IPO Restricted Share Unit Scheme acquired 370,000 shares on the open market between 14 and 22 April 2026. The purchases, settled from 16 to 24 April, were executed at an average price of HK$39.1069 per share, bringing the cash outlay to approximately HK$14.47 million.</p>\n<p>The newly acquired shares represent about 0.006% of Hansoh’s total issued share capital. Prior to the transaction, the RSU trustee held 1.19 million shares. Factoring in the April 17 issuance of 9.00 million new shares to the trustee under the scheme, the post-purchase holding rose to 10.56 million shares.</p>\n<p>The board stated it will continue to monitor the scheme and may authorise further market purchases or RSU grants at its discretion, subject to Hong Kong Listing Rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1145678598","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145678598","pubTimestamp":1777545914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) disclosed that the trustee of its Post-IPO Restricted Share Unit Scheme acquired 370,000 shares on the open market between 14 and 22 April...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"翰森制药以每股39.11港元购买370,000股受限制股份单位计划股份，耗资1447万港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) disclosed that the trustee of its Post-IPO Restricted Share Unit Scheme acquired 370,000 shares on the open market between 14 and 22 April 2026. The purchases, settled from 16 to 24 April, were executed at an average price of HK$39.1069 per share, bringing the cash outlay to approximately HK$14.47 million.\nThe newly acquired shares represent about 0.006% of Hansoh’s total issued share capital. Prior to the transaction, the RSU trustee held 1.19 million shares. Factoring in the April 17 issuance of 9.00 million new shares to the trustee under the scheme, the post-purchase holding rose to 10.56 million shares.\nThe board stated it will continue to monitor the scheme and may authorise further market purchases or RSU grants at its discretion, subject to Hong Kong Listing Rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145678598","isCrawlerRequest":true}